Department of Radiology, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan; Department of Radiation Oncology, St. Luke's International Hospital, 9-1 Akashicho, Chuo-ku, Tokyo, 104-8560, Japan.
Department of Radiology, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan; Department of Radiology, Teikyo University Hospital, 2-11-1, Kaga, Itabashi-ku, Tokyo, 173-8606, Japan; Department of Radiation Oncology, Mitsui Memorial Hospital, 1, Kandaizumicho, Chiyoda-ku, Tokyo, 101-8643, Japan.
Breast. 2020 Aug;52:88-94. doi: 10.1016/j.breast.2020.05.003. Epub 2020 May 14.
Because primary squamous cell carcinoma (SCC) of the breast is a rare disease, the standard therapy has not been established. We examined the clinical outcomes of postoperative adjuvant radiotherapy for breast SCC.
We conducted a multicenter retrospective cohort study. Patients diagnosed with primary breast SCC who received adjuvant radiotherapy as part of their primary definitive treatment were included. Overall survival (OS), breast cancer-specific survival (BCSS), and recurrence-free interval (RFi) were evaluated.
Between January 2002 and December 2017, 25 breast SCC patients received adjuvant radiotherapy as a primary treatment were included. Median follow-up time was 43.5 months. Three (12%), fifteen (60%) and seven (28%) patients had clinical stage I, II and III disease, respectively. Fourteen patients underwent breast-conserving surgery and subsequent adjuvant radiotherapy. Eleven patients underwent mastectomy and post-mastectomy radiotherapy. Ten patients received regional lymph node irradiation. Nine (36%) patients had disease recurrence. The first site of recurrence was locoregional in five, but distant metastasis arose in one. Concurrent local and distant metastasis were seen in two. Six cases of local recurrence occurred within the irradiated site. Seven patients died, and six of the deaths were due to breast cancer. Five-year OS, BCSS, and Rfi were 69%, 70%, and 63%, respectively. In multivariate analysis, age and lymphatic invasion were associated with increased risk of recurrence.
Breast SCC has a high incidence of locoregional recurrence and poor prognosis. Age and lymphatic invasion are significant risk factors for recurrence.
由于原发性乳腺鳞状细胞癌（SCC）是一种罕见疾病，因此尚未确立标准的治疗方法。我们研究了术后辅助放疗对乳腺 SCC 的临床疗效。
我们进行了一项多中心回顾性队列研究。纳入了接受辅助放疗作为主要根治性治疗一部分的原发性乳腺 SCC 患者。评估了总生存期（OS）、乳腺癌特异性生存期（BCSS）和无复发生存期（RFi）。
2002 年 1 月至 2017 年 12 月，共有 25 例乳腺 SCC 患者接受了辅助放疗作为主要治疗，中位随访时间为 43.5 个月。3 例（12%）、15 例（60%）和 7 例（28%）患者的临床分期分别为 I、II 和 III 期。14 例患者接受保乳手术和后续辅助放疗，11 例患者接受乳房切除术和术后放疗，10 例患者接受区域淋巴结照射。9 例（36%）患者出现疾病复发。局部复发的首次部位为 5 例，远处转移 1 例，局部和远处同时转移 2 例。6 例局部复发发生在照射部位内。7 例患者死亡，其中 6 例死于乳腺癌。5 年 OS、BCSS 和 Rfi 分别为 69%、70%和 63%。多因素分析显示，年龄和淋巴血管侵犯与复发风险增加相关。
乳腺 SCC 局部复发率高，预后差。年龄和淋巴血管侵犯是复发的显著危险因素。
